Symbols / CNSP Stock $2.47 +0.82% CNS Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NCM
CNSP (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors. The company's drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies. It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas.

Stock Fundamentals
Scroll to Statements
Market Cap 2.00M Enterprise Value -4.87M Income -15.85M Sales — Book/sh 7.15 Cash/sh 8.87
Dividend Yield — Payout 0.00% Employees — IPO — P/E 0.00 Forward P/E -6.33
PEG — P/S — P/B 0.35 P/C — EV/EBITDA 0.30 EV/Sales —
Quick Ratio 1.76 Current Ratio 1.98 Debt/Eq 7.26 LT Debt/Eq — EPS (ttm) -35.75 EPS next Y -0.39
EPS Growth — Revenue Growth — Earnings 2026-03-31 ROA -115.35% ROE -296.30% ROIC —
Gross Margin 0.00% Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 811.45K Shs Float 715.83K Short Float 6.66%
Short Ratio 1.17 Short Interest — 52W High 34.80 52W Low 1.90 Beta 0.49 Avg Volume 32.71K
Volume 4.58K Target Price $10.00 Recom None Prev Close $2.45 Price $2.47 Change 0.82%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$10.00
Mean price target
2. Current target
$2.47
Latest analyst target
3. DCF / Fair value
$-154.35
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.47
Low
$10.00
High
$10.00
Mean
$10.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-09-12 up Maxim Group Hold → Buy $20
2025-03-25 down Maxim Group Buy → Hold —
News
RSS: Latest CNSP news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
15.99
+7.28%
14.90
-21.01%
18.87
+23.57%
15.27
Research And Development
9.77
+5.19%
9.29
-34.09%
14.10
+51.56%
9.30
Selling General And Administration
6.21
+10.74%
5.61
+17.66%
4.77
-20.07%
5.97
General And Administrative Expense
6.21
+10.74%
5.61
+17.66%
4.77
-20.07%
5.97
Other Gand A
6.21
+10.74%
5.61
+17.66%
4.77
-20.07%
5.97
Total Expenses
15.99
+7.28%
14.90
-21.01%
18.87
+23.57%
15.27
Operating Income
-15.99
-7.28%
-14.90
+21.01%
-18.87
-23.57%
-15.27
Total Operating Income As Reported
-15.99
-7.28%
-14.90
+21.01%
-18.87
-23.57%
-15.27
EBITDA
-15.83
-6.69%
-14.84
+21.21%
-18.83
-23.45%
-15.26
Normalized EBITDA
-15.83
-6.69%
-14.84
+21.21%
-18.83
-23.45%
-15.26
Reconciled Depreciation
0.00
+18.51%
0.00
-20.03%
0.00
-64.83%
0.01
EBIT
-15.84
-6.70%
-14.84
+21.21%
-18.84
-23.39%
-15.27
Net Income
-15.85
-6.68%
-14.86
+21.18%
-18.85
-23.42%
-15.27
Pretax Income
-15.85
-6.68%
-14.86
+21.18%
-18.85
-23.42%
-15.27
Net Non Operating Interest Income Expense
0.14
+213.88%
0.04
+217.98%
0.01
+297.55%
-0.01
Interest Expense Non Operating
0.02
-5.52%
0.02
+16.77%
0.01
+96.46%
0.01
Net Interest Income
0.14
+213.88%
0.04
+217.98%
0.01
+297.55%
-0.01
Interest Expense
0.02
-5.52%
0.02
+16.77%
0.01
+96.46%
0.01
Interest Income Non Operating
0.15
+155.19%
0.06
+117.65%
0.03
0.00
Interest Income
0.15
+155.19%
0.06
+117.65%
0.03
0.00
Other Income Expense
-0.00
—
—
—
Other Non Operating Income Expenses
-0.00
—
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-15.85
-6.68%
-14.86
+21.18%
-18.85
-23.42%
-15.27
Net Income From Continuing Operation Net Minority Interest
-15.85
-6.68%
-14.86
+21.18%
-18.85
-23.42%
-15.27
Net Income From Continuing And Discontinued Operation
-15.85
-6.68%
-14.86
+21.18%
-18.85
-23.42%
-15.27
Net Income Continuous Operations
-15.85
-6.68%
-14.86
+21.18%
-18.85
-23.42%
-15.27
Normalized Income
-15.85
-6.68%
-14.86
+21.18%
-18.85
-23.42%
-15.27
Net Income Common Stockholders
-15.85
-6.68%
-14.86
+21.18%
-18.85
-23.42%
-15.27
Diluted EPS
—
-466.89
+99.49%
-91,068.72
+68.40%
-288,191.21
Basic EPS
—
-466.89
+99.49%
-91,068.72
+68.40%
-288,191.21
Basic Average Shares
—
0.03
+15273.43%
0.00
+290.57%
0.00
Diluted Average Shares
—
0.03
+15273.43%
0.00
+290.57%
0.00
Diluted NI Availto Com Stockholders
-15.85
-6.68%
-14.86
+21.18%
-18.85
-23.42%
-15.27
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
8.62
-0.89%
8.70
+411.56%
1.70
-86.97%
13.05
Current Assets
8.10
-6.42%
8.66
+444.16%
1.59
-87.34%
12.56
Cash Cash Equivalents And Short Term Investments
7.20
+11.45%
6.46
+1077.53%
0.55
-94.54%
10.06
Cash And Cash Equivalents
7.20
+11.45%
6.46
+1077.53%
0.55
-94.54%
10.06
Cash Financial
—
—
0.55
-94.54%
10.06
Receivables
0.00
-100.00%
0.88
0.00
—
Accounts Receivable
0.00
-100.00%
0.88
0.00
—
Prepaid Assets
—
—
—
2.51
Current Deferred Assets
0.05
+120.41%
0.02
-89.83%
0.20
0.00
Other Current Assets
0.86
-33.82%
1.29
+54.12%
0.84
-66.54%
2.51
Total Non Current Assets
0.52
+1126.97%
0.04
-61.31%
0.11
-77.55%
0.49
Net PPE
0.02
+194.80%
0.01
+21.73%
0.00
-12.91%
0.01
Non Current Deferred Assets
—
—
—
0.00
Non Current Prepaid Assets
0.50
+1280.63%
0.04
-65.22%
0.10
-78.30%
0.48
Total Liabilities Net Minority Interest
4.10
+62.46%
2.52
-58.84%
6.13
+24.65%
4.92
Current Liabilities
4.10
+62.46%
2.52
-58.84%
6.13
+24.65%
4.92
Payables And Accrued Expenses
3.77
+71.61%
2.20
-62.31%
5.83
+29.31%
4.51
Payables
—
—
—
3.68
Accounts Payable
—
—
—
3.68
Current Accrued Expenses
—
—
—
0.83
Current Debt And Capital Lease Obligation
0.33
+0.77%
0.33
+8.40%
0.30
-26.63%
0.41
Current Debt
0.33
+0.77%
0.33
+8.40%
0.30
-26.63%
0.41
Total Non Current Liabilities Net Minority Interest
0.00
0.00
0.00
0.00
Stockholders Equity
4.52
-26.78%
6.18
+239.36%
-4.43
-154.50%
8.13
Common Stock Equity
4.52
-26.78%
6.18
+239.36%
-4.43
-154.50%
8.13
Capital Stock
0.00
+436.44%
0.00
+5800.00%
0.00
-99.88%
0.00
Common Stock
0.00
+436.44%
0.00
+5800.00%
0.00
-99.88%
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
0.62
+426.58%
0.12
+56806.28%
0.00
+290.57%
0.00
Ordinary Shares Number
0.62
+426.58%
0.12
+56806.28%
0.00
+290.57%
0.00
Additional Paid In Capital
104.80
+15.67%
90.60
+39.10%
65.13
+10.69%
58.85
Retained Earnings
-100.28
-18.77%
-84.42
-21.36%
-69.57
-37.17%
-50.72
Total Equity Gross Minority Interest
4.52
-26.78%
6.18
+239.36%
-4.43
-154.50%
8.13
Total Capitalization
4.52
-26.78%
6.18
+239.36%
-4.43
-154.50%
8.13
Working Capital
4.00
-34.76%
6.13
+235.06%
-4.54
-159.41%
7.64
Invested Capital
4.85
-25.40%
6.50
+257.40%
-4.13
-148.36%
8.54
Total Debt
0.33
+0.77%
0.33
+8.40%
0.30
-26.63%
0.41
Net Tangible Assets
4.52
-26.78%
6.18
+239.36%
-4.43
-154.50%
8.13
Tangible Book Value
4.52
-26.78%
6.18
+239.36%
-4.43
-154.50%
8.13
Current Notes Payable
0.33
+0.77%
0.33
+8.40%
0.30
-26.63%
0.41
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-13.81
+19.30%
-17.11
-21.03%
-14.14
-33.93%
-10.56
Cash Flow From Continuing Operating Activities
-13.81
+19.30%
-17.11
-21.03%
-14.14
-33.93%
-10.56
Net Income From Continuing Operations
-15.85
-6.68%
-14.86
+21.18%
-18.85
-23.42%
-15.27
Depreciation Amortization Depletion
0.00
+18.51%
0.00
-20.03%
0.00
-64.83%
0.01
Depreciation
0.00
+18.51%
0.00
-20.03%
0.00
-64.83%
0.01
Depreciation And Amortization
0.00
+18.51%
0.00
-20.03%
0.00
-64.83%
0.01
Other Non Cash Items
—
0.60
—
—
Stock Based Compensation
0.19
-77.62%
0.84
-16.72%
1.01
-16.26%
1.20
Asset Impairment Charge
—
—
0.00
-100.00%
0.33
Operating Gains Losses
0.00
+1446.84%
-0.00
-138.15%
0.00
-83.99%
0.00
Gain Loss On Sale Of PPE
0.00
+1446.84%
-0.00
-138.15%
0.00
-83.99%
0.00
Change In Working Capital
1.85
+149.95%
-3.69
-199.86%
3.70
+16.90%
3.16
Change In Prepaid Assets
0.30
+604.90%
-0.06
-102.52%
2.38
+176.28%
0.86
Change In Payables And Accrued Expense
1.54
+142.45%
-3.63
-374.91%
1.32
-42.62%
2.30
Change In Accrued Expense
—
—
—
0.60
Change In Payable
—
—
—
1.70
Change In Account Payable
—
—
—
1.70
Investing Cash Flow
-0.02
-333.98%
-0.00
-7.36%
-0.00
+11.78%
-0.00
Cash Flow From Continuing Investing Activities
-0.02
-333.98%
-0.00
-7.36%
-0.00
+11.78%
-0.00
Net PPE Purchase And Sale
-0.02
-333.98%
-0.00
-7.36%
-0.00
+11.78%
-0.00
Purchase Of PPE
-0.02
-333.98%
-0.00
-7.36%
-0.00
+11.78%
-0.00
Capital Expenditure
-0.02
-333.98%
-0.00
-7.36%
-0.00
+11.78%
-0.00
Financing Cash Flow
14.57
-36.74%
23.03
+396.63%
4.64
-70.30%
15.61
Cash Flow From Continuing Financing Activities
14.57
-36.74%
23.03
+396.63%
4.64
-70.30%
15.61
Net Issuance Payments Of Debt
-0.30
+1.08%
-0.30
+31.44%
-0.44
-2.58%
-0.43
Repayment Of Debt
-0.30
+1.08%
-0.30
+31.44%
-0.44
-2.58%
-0.43
Long Term Debt Payments
—
—
—
—
Net Long Term Debt Issuance
—
—
—
—
Short Term Debt Payments
-0.30
+1.08%
-0.30
+31.44%
-0.44
-2.58%
-0.43
Net Short Term Debt Issuance
-0.30
+1.08%
-0.30
+31.44%
-0.44
-2.58%
-0.43
Net Common Stock Issuance
14.04
-39.92%
23.38
+908.65%
2.32
-85.55%
16.04
Common Stock Payments
-0.00
0.00
—
—
Repurchase Of Capital Stock
-0.00
0.00
—
—
Proceeds From Stock Option Exercised
0.00
-82.99%
0.02
-99.28%
2.96
+108211.59%
0.00
Net Other Financing Charges
0.82
+1326.15%
-0.07
+67.10%
-0.20
—
Changes In Cash
0.74
-87.49%
5.91
+162.19%
-9.51
-288.22%
5.05
Beginning Cash Position
6.46
+1077.53%
0.55
-94.54%
10.06
+100.93%
5.00
End Cash Position
7.20
+11.45%
6.46
+1077.53%
0.55
-94.54%
10.06
Free Cash Flow
-13.83
+19.21%
-17.12
-21.02%
-14.14
-33.91%
-10.56
Interest Paid Supplemental Data
0.02
+12.27%
0.01
-1.49%
0.01
+70.56%
0.01
Income Tax Paid Supplemental Data
0.00
0.00
0.00
0.00
Common Stock Issuance
14.05
-39.91%
23.38
+908.65%
2.32
-85.55%
16.04
Issuance Of Capital Stock
14.05
-39.91%
23.38
+908.65%
2.32
-85.55%
16.04
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category